Quantcast

Latest Atritech Inc. Stories

2011-03-03 07:30:00

NATICK, Mass., March 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Atritech, Inc. of Plymouth, Minnesota. The completion of the transaction follows the signing of a definitive merger agreement announced on January 19, 2011. Atritech's WATCHMAN® Left Atrial Appendage Closure Technology gives Boston Scientific an innovative product designed for atrial fibrillation patients with high stroke risk....

2011-01-19 07:30:00

NATICK, Mass., Jan. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, Inc., a privately held company based in Plymouth, Minnesota. Atritech has developed a novel device designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke. The agreement calls for an upfront payment of $100 million plus additional...

2010-11-02 17:55:00

MINNEAPOLIS, Nov. 2, 2010 /PRNewswire/ -- Atritech, Inc. today announced initial enrollment into its confirmatory study, PREVAIL, comparing the WATCHMAN® Left Atrial Appendage Closure Device to long term warfarin therapy in patients with atrial fibrillation. Doctors at Central Baptist Hospital in Lexington, Kentucky enrolled the first patient. The WATCHMAN® Device is designed to keep harmful sized blood clots from entering a patient's blood stream,...

2010-10-01 14:54:00

MINNEAPOLIS, Oct. 1 /PRNewswire/ -- Atritech announces German reimbursement coverage of the left atrial appendage closure procedure in 2011. The 2011 G-DRG (German Diagnosis Related Group) Catalog recently published on the InEK website (www.g-drg.de) adds left atrial appendage closure procedure to an existing G-DRG code. Atritech's WATCHMAN Left Atrial Appendage Closure Technology is a device alternative to long term warfarin therapy in patients with atrial fibrillation. The WATCHMAN is...

2010-03-18 15:00:00

MINNEAPOLIS, March 18 /PRNewswire/ -- Atritech, Inc., an emerging medical device company, announced today that it has obtained clarity from the U.S. Food and Drug Agency (FDA) on the regulatory path towards full approval of its WATCHMAN® Left Atrial Appendage (LAA) Closure Technology in the United States. In a recent letter received from the FDA, the agency requested that a confirmatory study be conducted to further substantiate the safety and effectiveness of the...

571af202195a5bc67dbdd93b08b2a0601
2009-03-29 13:00:00

An experimental device to treat a common heart problem that can lead to stroke showed promising results in a large clinical study, but carries some risk, according to new research reported on Saturday. The device, known as the Watchman and made by privately held Atritech Inc., is the first to try to permanently treat atrial fibrillation, a common heart rhythm disorder afflicting about 2.2 million Americans.   Roughly 15 percent of strokes occur in people with atrial fibrillation,...

2009-03-26 10:12:00

Company scheduled to announce PROTECT AF results on March 28th at ACC. MINNEAPOLIS, March 26 /PRNewswire/ -- Atritech, Inc. a clinical stage medical device company, announced today that it has completed a $30 million round of financing. Thomas, McNerney & Partners led the round along with a substantial investment from Split Rock Partners and insider investments from Prism Ventures, Tullis-Dickerson and Vector Group. Over the past 3 years, the Company has raised approximately $75...

2009-02-19 08:52:00

MINNEAPOLIS, Feb. 19 /PRNewswire/ -- Atritech, Inc. announced the upcoming presentation of the PROTECT AF trial results comparing the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation. The results will be unveiled at the Late Breaking Clinical Trial session during the I2 Summit Scientific Meeting at 8:30 am on March 28, 2009. The I2 Summit is part of the Annual Meeting of the...

2008-08-18 12:00:55

MINNEAPOLIS, Aug. 18 /PRNewswire/ -- Atritech, Inc. today announced the filing of its Pre-Market Approval Application (PMA) to the Food and Drug Administration (FDA). The PMA contains the results of the PROTECT AF Clinical Trial which began enrollment in early 2005. PROTECT AF evaluated the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Technology versus the current standard of care, warfarin, in patients with non-valvular atrial fibrillation at risk of stroke. The trial enrolled 800...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related